What pelacarsen is
Pelacarsen is an antisense oligonucleotide, a short synthetic strand of nucleic acid designed to bind the messenger RNA that carries instructions for making apolipoprotein(a), the protein that defines lipoprotein(a), or Lp(a). Binding the RNA prevents the protein from being made, so the liver releases less Lp(a) into the blood. It was discovered by Ionis Pharmaceuticals and developed by Novartis under the code name TQJ230. It is given as an injection under the skin.
Why the target looked so promising
Lp(a) is a cholesterol-carrying particle whose blood level is largely set by genetics. That makes it one of the clearest examples of a drug target supported by human genetic evidence:
- A 2009 genetic study in the New England Journal of Medicine found that variants in the LPA gene that raise Lp(a) levels were associated with substantially higher odds of coronary disease, with odds ratios of 1.70 and 1.92 for two independent variants.
- A 2009 study in JAMA found that people with genetically elevated Lp(a) had a higher risk of heart attack, supporting a causal role.
Because diet and exercise barely affect Lp(a), and no approved drug specifically lowers it, a drug that cut Lp(a) and prevented heart attacks would fill a large gap. Drug targets with genetic support have historically been more likely to succeed. See What Is Genomics?
Clinical evidence
Phase 2: Lp(a) lowering
In a Phase 2 trial of 286 patients with elevated Lp(a) and established cardiovascular disease, published in 2020, pelacarsen reduced Lp(a) in a dose-dependent manner. Mean decreases ranged from 35% at the lowest dose to 80% at 20 mg weekly, compared with 6% with placebo. The most common adverse events were injection-site reactions.
Phase 3: Lp(a)HORIZON
Lp(a)HORIZON was designed to answer the question that matters: does lowering Lp(a) with pelacarsen reduce heart attacks, strokes, and cardiovascular deaths?
| Feature | Detail |
|---|---|
| Participants | 8,323 adults with elevated Lp(a) and established cardiovascular disease |
| Design | Randomized, double-blind, placebo-controlled |
| Primary endpoint | Time to first major adverse cardiovascular event |
| Lp(a) reduction | 78% (presented at AHA Scientific Sessions 2026) |
| Primary result | Did not meet its primary endpoint |
On September 4, 2026, Ionis and Novartis announced that the trial did not meet its primary endpoint, while noting that "substantially lower" Lp(a) levels were achieved and that pelacarsen had an acceptable safety profile (company-reported, Ionis Form 8-K).
Full results were presented on November 7, 2026 at the American Heart Association's Scientific Sessions and published in the New England Journal of Medicine. According to the AHA summary of the presentation:
- Pelacarsen reduced Lp(a) by 78%, but there was no change in the time to a major adverse cardiovascular event.
- There was also no change in cardiovascular outcomes among patients with Lp(a) of 90 mg/dL or higher, the group many expected to benefit most.
- Serious adverse events occurred in 37.3% of the pelacarsen group and 41.1% of the placebo group. Anaphylaxis occurred in 19 patients receiving pelacarsen and none receiving placebo.
- About 21% of patients on pelacarsen and more than 7% on placebo stopped the study medication because of adverse reactions.
The study's senior author was quoted as saying the result did not mean Lp(a) is irrelevant, and called for further research.
Other trials
A smaller randomized trial in patients who require regular Lp(a) apheresis, a blood-filtering procedure, found that pelacarsen sharply reduced the need for apheresis sessions, with a placebo-adjusted Lp(a) change of −72% at 52 weeks (Lp(a)FRONTIERS APHERESIS, European Heart Journal, 2026). That trial measured the need for apheresis, not cardiovascular events.
Scientific perspective
Lp(a)HORIZON is one of the most important negative results in recent cardiovascular medicine because it breaks a chain of reasoning that looked unusually strong:
- Genetic studies indicated that higher Lp(a) causes heart disease.
- Pelacarsen lowered Lp(a) substantially and reliably.
- Lowering Lp(a) was therefore expected to reduce heart disease.
Step 3 did not hold in this trial. This is the core risk of any drug developed against a surrogate marker, as explained in What Is a Primary Clinical Trial Endpoint?. Several explanations remain possible, and none has been established: the residual Lp(a) after treatment may still have been too high for some patients, the benefit may require longer exposure than the trial provided, or Lp(a)'s contribution to risk in patients already receiving modern therapy may be smaller than genetic studies implied. Interpreting the result will depend on the detailed analyses now being published.
Development perspective
- Program status: ClinicalTrials.gov lists an open-label extension study as terminated and a planned Phase 3 study as withdrawn, both "following the outcome of the Lp(a)HORIZON study." Other pelacarsen studies remain listed as active; their future had not been confirmed in the sources we reviewed.
- Regulatory status: pelacarsen has no FDA approval. Without a positive outcomes trial, the path to approval for cardiovascular risk reduction is unclear.
- Read-across: the result directly affects other Lp(a)-lowering drugs in development, including olpasiran, which uses a different mechanism (small interfering RNA) and achieves deeper Lp(a) lowering. Whether that difference matters is exactly what the remaining outcomes trials will test.
Competitive context
Several Lp(a)-lowering drugs are in development using different technologies, including small interfering RNAs (olpasiran, lepodisiran, zerlasiran) and an oral small molecule (muvalaplin). To our knowledge, Lp(a)HORIZON was the first cardiovascular outcomes trial of a drug designed specifically to lower Lp(a) to report results. Its neutral result means that, for now, no Lp(a)-lowering therapy has demonstrated a reduction in cardiovascular events in a completed outcomes trial.
Development timeline
- Mar 7, 2017Phase 2 dose-ranging trial in patients with elevated Lp(a) and cardiovascular disease begins (286 participants). Registry
- Dec 12, 2019Lp(a)HORIZON Phase 3 cardiovascular outcomes trial begins. Registry
- Jan 1, 2020Phase 2 results published: dose-dependent Lp(a) reductions of 35% to 80%, versus 6% with placebo. Peer-reviewed
- Jul 16, 2026Lp(a)HORIZON reaches primary completion with 8,323 participants enrolled. Registry
- Sep 4, 2026Ionis and Novartis announce that Lp(a)HORIZON did not meet its primary endpoint of reducing cardiovascular events. Company-reported
- Oct 15, 2026Open-label extension study terminated by the sponsor following the Lp(a)HORIZON outcome. Registry
- Nov 7, 2026Full results presented at AHA Scientific Sessions 2026 and published in the New England Journal of Medicine: Lp(a) fell 78% with no reduction in major cardiovascular events. Scientific meeting
What could change the outlook
- Detailed analyses of Lp(a)HORIZON, including whether any prespecified subgroup, follow-up duration, or absolute Lp(a) reduction showed a different pattern.
- Whether Novartis continues any remaining pelacarsen studies, such as those listed as active on ClinicalTrials.gov, or discontinues the program.
- Results from other Lp(a)-lowering outcomes trials, which will show whether the HORIZON result reflects the drug, the trial design, or the Lp(a) hypothesis itself.
- Scientific explanations reconciling strong genetic evidence for Lp(a) with the neutral trial outcome.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Pelacarsen. Company-reported, not independently verified.
- Quarterly reportCompany-reportedOct 27, 2026
CONDENSED FINANCIAL REPORT
Selected innovative medicines projects awaiting regulatory decisions Completed submissions Product Indication US EU Japan News update Cosentyx Polymyalgia rheumatica Q1 2026 Q1 2026 Q1 2026 – Positive CHMP opinion – Efficacy supplement for IV regimen submitted to FDA Hidradenitis suppurativa, pediatrics aged 12+...
- Quarterly reportCompany-reportedOct 27, 2026
FINANCIAL REPORT Q3 2026
TQJ230 (pelacarsen) In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD), despite reducing Lp(a) levels in this study population.
- Trial resultsCompany-reportedSep 4, 2026
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated
Lp(a) and established cardiovascular disease (CVD) Ad hoc announcement pursuant to Art. 53 Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of...